GlassScriptPhysician profile
Frederick Fisher
NPI 1841211471
$4,239.25
in general payments reported to CMS, 2019-2025
22 companies · $760 in 2025
The $760 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,480 · 2020: $67.83 · 2021: $155 · 2022: $250 · 2023: $342 · 2024: $1,184 · 2025: $760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,198 · Travel and Lodging: $914 · Gift: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,197.71 |
| Travel and Lodging | $914.06 |
| Gift | $174.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,840.45 | 2019-2025 | Proclaim |
| Si-Bone, INC. | $1,015.67 | 2020-2024 | |
| Boston Scientific Corporation | $258.90 | 2022-2025 | Intracept, Patient Trial Kit, Wavewriter Alpha Prime 16 |
| Genesys Orthopedics Systems, L.L.C. | $174.60 | 2025 | Sacroiliac Joint Fusion System |
| Riwospine, INC. | $148.23 | 2022 | |
| Relievant Medsystems, INC. | $146.54 | 2021-2023 | Intracept |
| Abbvie INC. | $141.13 | 2021-2025 | |
| Nevro Corp. | $78.58 | 2019-2024 | Senza |
| Conetic Solutions, INC. | $75.00 | 2025 | |
| Globus Medical, INC. | $70.28 | 2025 | Vyrsa V1, Senza |
| Pfizer INC. | $46.77 | 2020-2021 | |
| Averitas Pharma INC. | $46.34 | 2024-2025 | Qutenza |
| Captiva Spine INC | $26.77 | 2021 | |
| Collegium Pharmaceutical, INC. | $26.09 | 2019 | |
| Spinal Simplicity, LLC | $23.19 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $20.19 | 2025 | Tremfya |
| Azurity Pharmaceuticals, INC. | $18.99 | 2024 | Horizant |
| Tersera Therapeutics LLC | $18.96 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $17.44 | 2025 | |
| Eagle Pharmaceuticals, INC. | $16.15 | 2024 | |
| Merck Sharp & Dohme LLC | $14.97 | 2024 | Bridion |
| Biohaven Pharmaceutical Holding Company LTD. | $14.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Fisher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.